Cochlear Implants
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - Rhode Island policy alerts
Know when Blue Cross Blue Shield - Rhode Island releases new policies or updates existing guidance.
Monitor payer policy activity
Coverage guidelines for cochlear implant devices (including hybrid systems) for BCBSRI members, with distinctions for Commercial Products and Medicare Advantage Plans. Affects providers seeking coverage/authorization for cochlear implantation procedures.
Effective 9/1/2026, CPT 69930 may be considered medically necessary for Commercial Products when the medical criteria in the online authorization tool for participating providers is met.
Effective 9/1/2026, prior authorization is recommended for Commercial Products via the online tool for participating providers.
Coverage Criteria for Cochlear Implants
Medicare Advantage — Cochlear Implantation (Bilateral)
Covered when ALL of the following are met for Medicare Advantage Plans:
CMS may cover individuals not meeting these criteria when implanted in FDA‑approved Category B investigational device exemption clinical trials or as routine costs in clinical trials per CMS guidance.
Commercial Products — Cochlear Implantation
Commercial Products:
Participating providers must use the payer's online authorization tool to determine whether medical criteria are satisfied; lack of required authorization or failure to meet tool criteria may result in denial.
Hybrid Cochlear Implant/Hearing Aid
Hybrid cochlear implant/hearing aid coverage:
Evaluate benefit from amplification using best‑aided recorded open‑set sentence recognition as appropriate.
Unilateral Hearing Loss
Unilateral hearing loss:
Medicare Advantage Plans follow CMS national/local coverage determinations; coverage for unilateral loss may differ for Commercial Products.
Initial coverage
Covered when ALL of the following are met:
Providers should use the online authorization tool (effective 9/1/2026) to confirm criteria; refer to CMS National Coverage Determination for additional guidance and to determine applicability to Medicare Advantage members.
Upgrades of an existing, functioning external cochlear implant sound processor performed solely to obtain aesthetic improvements or convenience (for example, a smaller-profile component or changing from a body-worn processor to a behind-the-ear model) are not covered. Replacement of internal and/or external components solely to upgrade to advanced or next‑generation technology is also not covered. Replacement of components may be considered medically necessary only when the existing component(s) are nonfunctional, cannot be repaired, or the inadequate response to the component(s) substantially interferes with the member’s activities of daily living.
Services that are determined to be not medically necessary under this policy, or that are identified as non‑covered benefits in the member’s subscriber agreement or employer contract, are excluded from coverage. Providers should verify member‑specific benefits and eligibility with the provider call center and be aware that plan documents supersede this medical policy.
If a provider renders services that are determined to be not medically necessary or are non‑covered benefits, the provider may not charge the member unless the member has been informed in advance and has agreed in writing to pay for the service.
Upgrades that are performed solely for convenience or for aesthetic reasons, including replacing a functioning external processor to obtain newer technology or a different form factor, are not medically necessary and therefore are not covered by this policy.
Services determined to be not medically necessary under this policy or under payer rules are not covered and may be denied. Providers must confirm coverage and obtain any required prior authorization or documented member agreement before providing care that could be considered not medically necessary to avoid claim denials or billing disputes.
Coding and Billing
| 69930 | Cochlear device implantation, with or without mastoidectomy |
| 69930 | Cochlear device implantation, with or without mastoidectomy |
| Q0 | Investigational clinical service provided in a clinical research study that is in an approved clinical research study |
| Q1 | Routine clinical service provided in a clinical research study that is in an approved clinical research study |
| 69930 | Cochlear device implantation, with or without mastoidectomy |
Provider Actions, Prior Authorization, and Billing Guidance
Prior authorization recommended for Commercial Products
Effective 9/1/2026, prior authorization is recommended (via the payer's online authorization tool) for participating providers submitting Commercial Product requests for CPT 69930.
- Use the online authorization tool for prior authorization workflows for Commercial Product members.
- Recommendation applies to participating providers beginning 9/1/2026.
Prior authorization via online tool required when criteria apply
CPT 69930 (cochlear device implantation, with or without mastoidectomy) may be considered medically necessary for Commercial Products only when the medical criteria in the online authorization tool for participating providers are met.
- Providers must use the online authorization tool to establish that the member meets the tool's medical criteria before billing under Commercial Products.
- Effective date for this requirement is 9/1/2026.
Upgrades and replacements not covered when for convenience or aesthetics
Replacement or upgrade of internal or external components solely for aesthetic reasons, convenience, or to obtain newer/next‑generation technology is considered not covered.
- Upgrades for smaller profile components or switching processor styles (e.g., body-worn to BTE) are considered convenience and not covered.
- Replacements solely to upgrade technology are not covered; replacement is covered only when components no longer function or interfere with activities of daily living and cannot be repaired.
Follow online authorization tool criteria for Commercial Products (high importance)
Providers must follow the online authorization tool criteria for Commercial Products and be aware that effective 9/1/2026 the tool governs medical necessity determinations for CPT 69930.
- Ensure authorization decisions and documentation align with the online tool for Commercial Product members.
- Participating providers should complete the tool workflow prior to scheduling the procedure to avoid coverage issues.
Clinical trial billing documentation — use Q0/Q1 modifiers
Claims for services rendered as part of FDA‑approved Category B investigational device exemption clinical trials or for routine clinical trial costs must include the appropriate clinical trial modifier: Q0 for investigational clinical services and Q1 for routine clinical services.
- Report Q0 with the cochlear implantation device and related device costs for investigational clinical services.
- Report Q1 for routine clinical services (not the device) when billing routine trial costs.
Provider verification of member benefits and eligibility
Verify member-specific benefits and eligibility with the provider call center prior to scheduling or performing services, as benefits and eligibility are determined by the member's subscriber agreement or employer agreement.
- Contact the provider call center for member benefit details.
- Subscriber/employer agreements supersede this medical policy for coverage decisions.
Prior authorization / authorization tool requirement may affect coverage
Lack of prior authorization or failure to meet the online authorization tool medical criteria for Commercial Products (effective 9/1/2026) may trigger denial or non‑coverage for CPT 69930.
- Obtain and document authorization via the online tool for participating providers to reduce risk of denial.
- Confirm the member meets the tool's medical criteria before proceeding.
Denial and billing risk for non‑covered or not medically necessary services
Services determined to be not medically necessary or otherwise non‑covered may be denied and, unless the member has been informed and agreed in writing in advance, the provider may not charge the member for those services.
- If a service is non‑covered or not medically necessary, obtain a written member agreement in advance if the member will pay out-of-pocket.
- Refer to participation agreements for billing provisions.
Background
A cochlear implant provides direct electrical stimulation to the auditory nerve for individuals with moderate‑to‑profound sensorineural hearing loss who receive limited benefit from hearing aids. The system has internal and external components; implantation is intended to restore sound awareness and improve communication for appropriately selected candidates.
Definitions and Key Terms
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.